Experimental Drug Found Effective in Slowing Alzheimer’s

by | Jul 29, 2015 | Health & Healing

Patients with mild Alzheimer’s disease who took Eli Lilly’s experimental drug solanezumab early in the course of their disease preserved more of their cognitive and functional ability, according to new Lilly data released on Wednesday.

Lilly presented new follow-up data from two large trials of the infused medicine on Wednesday at the Alzheimer’s Association International Conference (AAIC) in Washington.

Researchers and investors have been keen to see if the results would firm up solanezumab as a lead contender to be the first treatment to effectively slow progression of the memory-robbing disease.

In 2012, the original 18-month studies of solanezumab, called Expedition and Expedition 2, each included about 1,000 patients with mild to moderate disease. The drug failed to slow cognitive declines or loss of abilities of daily living for the entire patient population.

But when Lilly analyzed results only for mild patients, the data suggested solanezumab caused a significant 34 percent slowdown in mental decline and an 18 percent slowdown in loss of functional abilities compared to placebo, researchers said.

To better assess whether mildly impaired patients benefit from the drug, Lilly extended its two trials by another two years and only enrolled those with mild disease. 

Researchers continued to provide solanezumab to patients who had taken it during the studies and also allowed patients who had been given placebos to switch over to solanezumab.

Lilly had previously reported that after the first six months of the extension study, patients who had taken solanezumab all along continued to show a greater benefit than those who switched to the drug later.

Company researchers on Wednesday said that difference remained statistically significant 12 months into the extension trial and continued to a lesser degree at two years.

“Visually, when you look at a graph, the two patient groups are seen as parallel lines,” in terms of different cognition and functional abilities, said Hong Liu-Seifert, a research adviser at Lilly. “And we continued to see the two lines remain parallel to each other” over the two year extension.

Lilly said solanezumab was well tolerated during the extension study, having similar safety to that seen in earlier trials. 

But cardiac events were seen more frequently in the initial trials among patients taking solanezumab than in the placebo group, an issue that will be examined closely in a newer and larger trial called Expedition 3 that is now underway.

Should solanezumab prove successful in that 2,100-patient study of patients with mild Alzheimer’s, within several years it could become the first approved drug to slow the course of the disease affecting 5 million Americans, Lilly officials said.

John Boris, an analyst with SunTrust Robinson Humphrey, estimates it has potential to capture more than $10 billion in annual sales and boost Lilly earnings for years to come.

Company shares have jumped 24 percent so far this year, compared with average 12 percent gains for other large drugmakers, largely on faith in solanezumab.

Lilly’s Extension 3 study will only enroll patients shown by brain imaging tests to have beta amyloid brain plaques, and thus Alzheimer’s rather than other types of dementia. Lilly estimates 25 percent of patients in the failed earlier Expedition studies actually had no beta amyloid deposits, and therefore would not have benefited from solanezumab.

PROTEIN BLOCKING
Solanezumab works by blocking formation of a protein called beta amyloid believed to cause toxic brain plaques that are considered a hallmark of Alzheimer’s.

Eric Siemers, medical director for Lilly’s Alzheimer’s team, said if solanezumab can slow disease progression by roughly a third, as it did in the first two Phase III trials, that would be very meaningful to patients.

“In 18 months of treatment with solanezumab, patients could delay six months worth of progression” of Alzheimer’s, he said. “That gives you more opportunity to do things that are important to you, before you progress into later stages of the disease.”

Siemers said beta amyloid is believed to build up in the brain for 10 or 15 years and steadily kill neurons before Alzheimer’s symptoms appear.

Patients who took solanezumab from the start of earlier studies may have preserved many brain cells, he speculated, while those that began taking it later were not protected for the initial period. “They can’t get those brain cells back; they are gone forever.”

© 2015 Thomson/Reuters. All rights reserved.

CHARISMA NEWSLETTERS

Stay up-to-date with current issues, Christian teachings, entertainment news, videos & more.

The latest breaking Christian news you need to know about as soon as it happens.

Prophetic messages from respected leaders & news of how God is moving throughout the world. 


MORE FROM CHARISMA

Will the New Set of Seven Years on the Jewish Calendar Be Our Last?

Will the New Set of Seven Years on the Jewish Calendar Be Our Last?

Note: This is the second of a two-part series. For part one, click here. Beginning at sunset on Sunday, Sept. 25, our Jewish friends (and increasingly many Christians) will begin a two-day celebration of Rosh Hashanah, their time for new beginnings or a "new year."...

Is America Preparing the Way for a One-World Ruler?

Is America Preparing the Way for a One-World Ruler?

The culmination of history is approaching. The end of the world may be at hand. Yet Jesus tells us we should not be alarmed. Why? Because we are engraved in the palms of His hands. Because we are carried in His arms. Because we are the apple of His eye. The time is...

A ‘Davidic Anointing’ is Descending Upon Musical Instruments

A ‘Davidic Anointing’ is Descending Upon Musical Instruments

I once heard a testimony where the Holy Ghost was falling upon the people during worship. The preacher, R.W. Schambach, testified how the piano player got so filled with the Spirit that she fell off of the piano bench and the piano kept right on playing. No other...

Joyce Meyer: How You Can Make God’s Love Your Lifestyle

Joyce Meyer: How You Can Make God’s Love Your Lifestyle

I have made it a priority to study about love in the Word of God. Getting a revelation about how much God loves me and learning to receive His love has been life-changing for me. It’s been the key to being able to really enjoy my life because when I received God’s...

Mario Murillo: What God is Saying About America’s Destruction

Mario Murillo: What God is Saying About America’s Destruction

Many prophetic words released today shout one of these two headlines: America Is Past Hope and Will Be Destroyed America Is Favored and Will Never Be Destroyed Facebook oozes with voices claiming to be prophets or mouthpieces for God. The internet teems with...

How The Christian Community Can Change American Politics for Good

How The Christian Community Can Change American Politics for Good

A fascinating discovery has taken place recently in the state of California. Locals there attest that the wildfires that have ravaged the landscape, lives and livelihoods of residents for a decade don’t seem to be getting any better. They seem to be getting worse,...

RECENT ARTICLES

Former Atheist: How the Deconstruction of Your Christian Faith Can Actually Strengthen It

Best-selling author Lee Strobel, an atheist and investigative journalist who failed to disprove the resurrection of Jesus during two years of digging for evidence, believes Christians who properly...
Rod Parsley: Are You the Pharisee or the Tax Collector?

Rod Parsley: Are You the Pharisee or the Tax Collector?

As with all virtues, humility has an opposite: pride. It should not surprise us that revival and restoration begins with humility, because all “falling away” begins with pride. Pride sent the archangel Lucifer plummeting from the heights of glorious splendor near the...

What to Do with an Urgent Warning from the Lord

What to Do with an Urgent Warning from the Lord

Many people are receiving urgent warnings from the Lord about things taking place in the earth. Releasing those warnings can be difficult. Done the wrong way, people will turn a deaf ear and the last thing you want to do is breed fear. Maybe you aren't getting...

Prophetic Word: ‘You Will Taste the Rain of Heaven’

Prophetic Word: ‘You Will Taste the Rain of Heaven’

Get ready for a supernatural strength to take over the land. It is time for worldwide revival and for you to reclaim what God has promised. Don’t back down and give in to despair. God’s plan is in motion. I heard the Lord say, “The enemy has brought discouragement and...

Mario Murillo: The Fuse to a National Awakening

Mario Murillo: The Fuse to a National Awakening

A lot of churchgoers yearn for soothing sermons. Meanwhile, a growing company seeks to understand authority, brokenness and Resurrection life. Who are these “others” who have their eyes wide open? They are too loud for most. They pray longer and deeper than what is...

The Value of the Golden Aged Among Us

The Value of the Golden Aged Among Us

Sarah bore Isaac when she was 90 years old. Moses led the Israelites out of bondage when he was 80. God cared for them, carried them, and used them! If you are nearing or are already in your golden years, don’t despair. You have much to offer to those behind you. You...

Pin It on Pinterest